Gene Therapy Briefs: Regeneron Wins FDA Approval for First Neurosensory Gene Therapy
The FDA has granted accelerated approval to Regeneron Pharmaceuticals’ Otarmeni™ (lunsotogene parvec-cwha) as the first gene therapy designed to restore a neurosensory function to normal levels. Otarmeni is an adeno-associated virus vector-based gene …